Phase I study of everolimus in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC).

被引：0
|
作者：
Finn, R. S.
Poon, R. T. P.
Yau, T.
Klumpen, H.
Chen, L.
Kang, Y.
Kim, T.
Gomez-Martin, C.
Rodriguez-Lope, C.
Kunz, T.
Paquet, T.
Asubonteng, K.
Winkler, R. E.
Anak, O.
Sellami, D. B.
Bruix, J.
机构：
[1] Univ Calif Los Angeles, Los Angeles, CA USA
[2] Univ Hong Kong, Queen Mary Hosp, Hong Kong, Hong Kong, Peoples R China
[3] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands
[4] Natl Cheng Kung Univ Hosp, Tainan 70428, Taiwan
[5] Asan Med Ctr, Seoul, South Korea
[6] Seoul Natl Univ Hosp, Seoul 110744, South Korea
[7] Hosp 12 Octubre, E-28041 Madrid, Spain
[8] IDIBAPS, Hosp Clin, Liver Unit, BCLC Grp, Barcelona, Spain
[9] Novartis Pharmaceut, Florham Pk, NJ USA
[10] Novartis Pharma AG, Basel, Switzerland
[11] Novartis Pharmaceut, E Hanover, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4074
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase I/II study of everolimus in patients with advanced hepatocellular carcinoma (HCC)
    Blaszkowsky, L. S.
    Abrams, T. A.
    Miksad, R. A.
    Zheng, H.
    Meyerhardt, J. A.
    Schrag, D.
    Kwak, E. L.
    Fuchs, C.
    Ryan, D. P.
    Zhu, A. X.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [2] A phase I study of bavituximab and sorafenib in patients with advanced hepatocellular carcinoma (HCC)
    Yopp, Adam
    Arriega, Yuii
    Singal, Amit
    Mansour, John
    Bach, Glen
    Thorpe, Phillip
    [J]. CANCER RESEARCH, 2012, 72
  • [3] Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma
    Finn, Richard S.
    Poon, Ronnie T. P.
    Yau, Thomas
    Klumpen, Heinz-Josef
    Chen, Li-Tzong
    Kang, Yoon-Koo
    Kim, Tae-You
    Gomez-Martin, Carlos
    Rodriguez-Lope, Carlos
    Kunz, Tiffany
    Paquet, Thierry
    Brandt, Ulrike
    Sellami, Dalila
    Bruix, Jordi
    [J]. JOURNAL OF HEPATOLOGY, 2013, 59 (06) : 1271 - 1277
  • [4] A phase I/II study of bavituximab and sorafenib in advanced hepatocellular carcinoma (HCC)
    Yopp, Adam Charles
    Singal, Amit G.
    Arriaga, Yull Edwin
    Verma, Udit N.
    Shan, Joseph
    Kallinteris, Nikoletta L.
    Beg, Muhammad Shaalan
    Mansour, John C.
    Zhu, Hao
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [5] A phase I trial of the combination of temsirolimus (TEM) and sorafenib (SOR) in advanced hepatocellular carcinoma (HCC)
    Kelley, R. K.
    Nimeiri, H. S.
    Vargo, M. T.
    Bergsland, E. K.
    Ko, A. H.
    Munster, P. N.
    Reinert, A.
    Mulcahy, M. F.
    Benson, A. B.
    Venook, A. P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [6] Phase I/II study of E7050 (golvantinib) in combination with sorafenib in patients (pts) with advanced hepatocellular carcinoma (HCC): Phase I results
    O'Neil, Bert H.
    Bendell, Johanna C.
    Modiano, Manuel R.
    Machiels, Jean-Pascal H.
    Versola, Melissa Jo
    Hodge, Jeff Paul
    Sawarna, Karen
    Tse, Nielson
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [7] Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)
    Ghassan K. Abou-Alfa
    Chia-Jui Yen
    Chih-Hung Hsu
    Joseph O’Donoghue
    Volkan Beylergil
    Shutian Ruan
    Neeta Pandit-Taskar
    Bolorsukh Gansukh
    Serge K. Lyashchenko
    Jennifer Ma
    Peter Wan
    Yu-Yun Shao
    Zhong-Zhe Lin
    Catherine Frenette
    Bert O’Neil
    Lawrence Schwartz
    Peter M. Smith-Jones
    Toshihiko Ohtomo
    Takayoshi Tanaka
    Hideo Morikawa
    Yuko Maki
    Norihisa Ohishi
    Ya-Chi Chen
    Tamara Agajanov
    Frederic Boisserie
    Laura Di Laurenzio
    Ray Lee
    Steven M. Larson
    Ann-Lii Cheng
    Jorge A. Carrasquilo
    [J]. Cancer Chemotherapy and Pharmacology, 2017, 79 : 421 - 429
  • [8] A phase II study of sorafenib in combination with tegafur/uracil (UFT) for Asian patients with advanced hepatocellular carcinoma (HCC)
    Shen, Y.
    Hsu, C.
    Hsu, C.
    Lin, Z.
    Chen, P.
    Shao, Y.
    Huang, T.
    Ding, Y.
    Cheng, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [9] Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)
    Abou-Alfa, Ghassan K.
    Yen, Chia-Jui
    Hsu, Chih-Hung
    O'Donoghue, Joseph
    Beylergil, Volkan
    Ruan, Shutian
    Pandit-Taskar, Neeta
    Gansukh, Bolorsukh
    Lyashchenko, Serge K.
    Ma, Jennifer
    Wan, Peter
    Shao, Yu-Yun
    Lin, Zhong-Zhe
    Frenette, Catherine
    O'Neil, Bert
    Schwartz, Lawrence
    Smith-Jones, Peter M.
    Ohtomo, Toshihiko
    Tanaka, Takayoshi
    Morikawa, Hideo
    Maki, Yuko
    Ohishi, Norihisa
    Chen, Ya-Chi
    Agajanov, Tamara
    Boisserie, Frederic
    Di Laurenzio, Laura
    Lee, Ray
    Larson, Steven M.
    Cheng, Ann-Lii
    Carrasquilo, Jorge A.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (02) : 421 - 429
  • [10] A phase I/II study of TRC105 in combination with sorafenib in hepatocellular carcinoma (HCC)
    Duffy, Austin G.
    Ma, Chi
    Ulahannan, Susanna Varkey
    Makarova-Rusher, Oxana V.
    Fioravanti, Suzanne
    Walker, Melissa
    Venkatesan, Aradhana
    Turkbey, Ismail B.
    Choyke, Peter L.
    Trepel, Jane B.
    Cao, Liang
    Compton, Kathryn
    Figg, William Douglas
    Greten, Tim F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
12345